Symposium jointly organized with FIND
12 October 2017, 13:00-17:00, Guadalajara, Mexico
Chairpersons: Catharina Boehme, FIND, and Daniela Cirillo, San Raffaele Scientific Institute, NDWG Co-Chairs
Presentations:
Session 1: The global TB diagnostics pipeline: Progress and needs
- Welcome address, Catharina Boehme and Daniela Cirillo
- Overview and updates on recent developments against needs, Claudia Denkinger, FIND
- The funding gap in TB diagnostics R&D - Results from report on TB research funding trends, Erica Lessem, TAG
- Use of genome-wide expression for diagnosing active TB and potential for non-sputum based diagnosis, Purvesh Khatri, Stanford University
- Potential of cell-free DNA in plasma or urine for rapid detection of Mycobacterium tuberculosis, Niaz Banaei, Stanford University
Session 2: Supporting development of new tests for LTBI: Recent advances
- Incipient TB assays to support TB elimination: Opportunities and challenges, Samuel Schumacher, FIND
- Estimating the impact of a test for incipient TB: Preliminary results of a transmission and cost effectiveness model, Suzanne Verver, Erasmus University Medical Center
- The current landscape of discovery and early development in LTBI and incipient TB, Gavin Churchyard, Aurum Institute (Presentation not available)
Session 3: Progress in the use of next-generation sequencing (NGS) for surveillance, diagnosis and patient management
- Programmatic Implementation of NGS for TB and future plans for the ReSeqTB knowledgebase Timothy Rodwell, FIND / UCSD
- Predicting susceptibility to first-line drugs: Can we phase out phenotypic DST and transition to WGS-led diagnostics? Timothy Walker, University of Oxford (Presentation will be available later)
- WHO policy update: Interpretation of DST Christopher Gilpin, World Health Organization
Session 4: Panel discussion: Challenges in molecular testing roll-out on a programmatic level
Introduction by the Moderator: Martina Casenghi, Core Group New Diagnostics Working Group